Despite decades of scientific progress, over 40% of biomanufacturing processes still rely on paper-based tools according to an estimation by HINA Bioventures, a Healthcare & Life Science growth investor.
However the gap between the lab bench and the digital age is now closing fast and becoming broadly viable.
The article by HINA Bioventures makes a compelling case that Bioprocessing 4.0 is not just a buzzword. Drawing on the broader arc of industrial revolutions, the authors frame the convergence of cloud computing, machine learning, and automation as the enabling layer that biomanufacturing has been waiting for. The barriers have been real — regulatory conservatism, legacy IT, data silos, cultural resistance — but the economics are shifting. Expanding physical capacity is expensive and slow; going digital is not.
What's at stake goes beyond efficiency. The authors argue that treating data as a strategic asset — accumulating and redeploying it across development and manufacturing — creates compounding value over time. For CDMOs, biosimilar manufacturers, biopharma companies, and even equipment suppliers, the business case looks different but equally strong.
And the horizon beyond Bioprocessing 4.0 is already coming into view: a Bioprocessing 5.0 era of largely autonomous laboratories, powered by large language models and synthetic biology.